After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...

A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio. | A rival bidder has emerged to ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

The ongoing investigation by Wyden and his Democratic compatriots from the Finance Committee has pointed the finger at ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Before joining Moderna, Cronin spent close to 20 years at Ogilvy, working within its global healthcare department in ...

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...

Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

Digging deeper into the BIO survey results, 94% of companies polled said they expect tariffs on the EU to drive up ...